Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial
- PMID: 25842469
Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial
Abstract
Rosmarinus officinalis L. is a medicinal plant with diverse activities including enhancement microcapillary perfusion. The present study aimed to investigate the clinical efficacy of rosemary oil in the treatment of androgenetic alopecia (AGA) and compare its effects with minoxidil 2%. Patients with AGA were randomly assigned to rosemary oil (n = 50) or minoxidil 2% (n = 50) for a period of 6 months. After a baseline visit, patients returned to the clinic for efficacy and safety evaluations every 3 months. A standardized professional microphotographic assessment of each volunteer was taken at the initial interview and after 3 and 6 months of the trial. No significant change was observed in the mean hair count at the 3-month endpoint, neither in the rosemary nor in the minoxidil group (P > .05). In contrast, both groups experienced a significant increase in hair count at the 6-month endpoint compared with the baseline and 3-month endpoint (P < .05). No significant difference was found between the study groups regarding hair count either at month 3 or month 6 (> .05). The frequencies of dry hair, greasy hair, and dandruff were not found to be significantly different from baseline at either month 3 or month 6 trial in the groups (P > .05). The frequency of scalp itching at the 3- and 6-month trial points was significantly higher compared with baseline in both groups (P < .05). Scalp itching, however, was more frequent in the minoxidil group at both assessed endpoints (P < .05). The findings of the present trial provided evidence with respect to the efficacy of rosemary oil in the treatment of AGA.
Similar articles
-
Multi-therapies in androgenetic alopecia: review and clinical experiences.Dermatol Ther. 2016 Nov;29(6):424-432. doi: 10.1111/dth.12390. Epub 2016 Jul 18. Dermatol Ther. 2016. PMID: 27424565 Review.
-
A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men.Skin Pharmacol Physiol. 2015;28(5):236-44. doi: 10.1159/000375320. Epub 2015 Mar 3. Skin Pharmacol Physiol. 2015. PMID: 25765348 Clinical Trial.
-
Androgenetic alopecia: an evidence-based treatment update.Am J Clin Dermatol. 2014 Jul;15(3):217-30. doi: 10.1007/s40257-014-0077-5. Am J Clin Dermatol. 2014. PMID: 24848508 Review.
-
A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women.J Am Acad Dermatol. 2011 Dec;65(6):1126-1134.e2. doi: 10.1016/j.jaad.2010.09.724. Epub 2011 Jun 23. J Am Acad Dermatol. 2011. PMID: 21700360 Clinical Trial.
-
Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial.Am J Clin Dermatol. 2007;8(5):285-90. doi: 10.2165/00128071-200708050-00003. Am J Clin Dermatol. 2007. PMID: 17902730 Clinical Trial.
Cited by
-
Complementary and alternative supplements: a review of dermatologic effectiveness for androgenetic alopecia.Proc (Bayl Univ Med Cent). 2023 Dec 20;37(1):111-117. doi: 10.1080/08998280.2023.2263829. eCollection 2024. Proc (Bayl Univ Med Cent). 2023. PMID: 38174012 Free PMC article. Review.
-
Potential application of PBM use in hair follicle organoid culture for the treatment of androgenic alopecia.Mater Today Bio. 2023 Nov 3;23:100851. doi: 10.1016/j.mtbio.2023.100851. eCollection 2023 Dec. Mater Today Bio. 2023. PMID: 38024838 Free PMC article. Review.
-
Immunological and Histological Studies of Different Concentrations of Rosmarinus officinalis and Thymus vulgaris Extracts on Thymus Gland of Chick Embryos.Toxics. 2023 Jul 19;11(7):625. doi: 10.3390/toxics11070625. Toxics. 2023. PMID: 37505590 Free PMC article.
-
Androgenetic Alopecia: Therapy Update.Drugs. 2023 Jun;83(8):701-715. doi: 10.1007/s40265-023-01880-x. Epub 2023 May 11. Drugs. 2023. PMID: 37166619 Free PMC article. Review.
-
Rosmarinus officinalis and Skin: Antioxidant Activity and Possible Therapeutical Role in Cutaneous Diseases.Antioxidants (Basel). 2023 Mar 9;12(3):680. doi: 10.3390/antiox12030680. Antioxidants (Basel). 2023. PMID: 36978928 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous